The present disclosure provides antibodies that bind to human GFRa3 and methods of using same. According to certain embodiments disclosed herein the antibodies are fully human antibodies that bind to human GFRa3. The antibodies of the disclosure are useful for the treatment of diseases and disorders associated with one or more GFRa3 biological activities including the treatment of acute or chronic pain conditions or inflammatory conditions.